NICE's reply

descriptionPublicationkeyboard_double_arrow_right Article 07 Jun 2011 English Publisher:BMJJournal:BMJ, volume 342, pages d3519-d3519 (issn: 0959-8138, eissn: 1468-5833,

Copyright policy )

Authors: Sean, Duffy;

doi: 10.1136/bmj.d3519

pmid: 21652753

NICE's reply

- Summary
- Subjects
- Metrics

Abstract

The National Institute for Health and Clinical Excellence (NICE) guideline aims to reduce the number of women dying from ovarian cancer because of late diagnoses.1 2 Evidence shows that the CA125 blood test is the most reliable and widely used tumour marker available. Because the four key symptoms are non-specific, it would be costly and of little clinical benefit …

Keywords

CA-125 Antigen, Biomarkers, Tumor, Humans, Female, United Kingdom, Quality of Health Care

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average